Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05667454 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MAD Trial: Myopia Atropine Dose

Study acronym: MAD
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 54 days later Mar 1, 2029 → Apr 24, 2029
See other at-risk trials from Erasmus Medical Center

Record History

  1. Enrollment closed, study ongoing Primary completion pushed from Mar 1, 2029 to Apr 24, 2029 · Completion date: Apr 1, 2029 to Apr 24, 2029 · Site details revised at 20 of 20 sitesv5 Show 3 more changesShow less
    • Primary completion pushed from Mar 1, 2029 to Apr 24, 2029
    • Completion date: Apr 1, 2029 to Apr 24, 2029
    • Site details revised at 20 of 20 sites
  2. Study sites: 24 to 20 Primary completion date: Dec 1, 2028 to Mar 1, 2029 · Completion date: Dec 1, 2028 to Apr 1, 2029 · Eligibility criteria shortened, about 2 wordsv4 Show 3 more changesShow less
    • Primary completion date: Dec 1, 2028 to Mar 1, 2029
    • Completion date: Dec 1, 2028 to Apr 1, 2029
    • Eligibility criteria shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites revised (24)v3 See this version in full on ClinicalTrials.gov ↗
  4. Trial status: Not Yet Recruiting to Recruiting Site details revised at 24 of 24 sitesv2 Show 1 more changeShow less
    • Site details revised at 24 of 24 sites
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this interventional study is to compare the efficacy of Atropine 0.05% to Atropine 0.5% treatment against progression of axial length in European children with progressive myopia, and to evaluate the safety, adherence, and reasons for nonresponse. Subjects will use Atropine eye drops for a period of 3 years, followed by a 2 year observational period.
Trial Details
NCT Number NCT05667454
Lead Sponsor Erasmus Medical Center
Collaborators: ZonMw: The Netherlands Organisation for Health Research and Development
Conditions Progressive Myopia
Enrollment 550 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov